Andrea S. Blevins Primeau

Four novel loci were identified in a multi-ancestry genome-wide association study (GWAS) that conferred an increased risk of developing pediatric acute myeloid leukemia (AML), according to a poster presented at the AACR Annual Meeting 2026.

Among pediatric patients with hemophilia A with inhibitors, immune tolerance induction (ITI) alone resulted in shorter time to inhibitor clearance compared with ITI plus emicizumab, according to results from the MOTIVATE study presented at the 2026 ASPHO Conference.

NXT007, a next-generation bispecific antibody, demonstrated promising efficacy and safety as prophylaxis among patients with moderate to severe hemophilia A with or without inhibitors, according to results of a phase 1/2 study presented at the 2026 ASPHO Conference.

A novel smartphone application has been developed to help patients with hemophilia manage their condition, including taking medication, send appointment reminders, record notes, and provide the ability to communicate and send reports to healthcare providers.

Treatment of chemotherapy -induced thrombocytopenia (CIT) with romiplostim significantly reduced the proportion of patients who required CIT-induced dose modifications compared with placebo, according to results from the phase 3 RECITE trial published in the New England Journal of Medicine.

An international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine specialists published consensus recommendations for the diagnosis and management of pediatric acute myeloid leukemia (AML) in the journal Blood.

Long-term treatment with acalabrutinib was associated with low rates of disease progression and a consistent safety profile among patients with chronic lymphocytic leukemia (CLL), according to the final results from the ASSURE study presented at the EHA 2026 Congress.

The combination of tafasitamab with lenalidomide and rituximab demonstrated efficacy in high-risk subgroups of patients with relapsed/refractory (R/R) follicular lymphoma (FL), according to a post hoc analysis of the inMIND trial presented at the EHA 2026 Congress.

CPX-351 treatment resulted in improved overall survival (OS) among patients with myelodysplastic-related (MR) acute myeloid leukemia (AML) who underwent hematopoietic transplantation (HCT), according to analysis of a phase 3 trial published in Blood Advances.

More than one-quarter of surveyed European countries did not have access to CD19 chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), according to the result of the IMPACT study published in JCO Global Oncology.